Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

Phase 4 Recruiting 500 enrolled Icahn School of Medicine at Mount Sinai Children's Hospital Medical Center, Cincinnati · collab Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab Seattle Children's Hospital · collab University of Florida · collab

NaSingle-groupOpen-labelBasic science

Summary

The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.

Timeline

Start: 2018-03-04
Primary completion: 2025-08
Completion: 2025-08

Publications

Zhang Q, Melchert PW, Awad A, McCurdy CR, Krone B, Newcorn J, Froehlich TE, Stein MA, Raeuscher J, Zhu HJ, Markowitz JS. Increased Plasma Concentrations of 6-oxo-Methylphenidate in CES1 G134E Carriers Following a Single Oral Dose of Methylphenidate. Med Chem Res. 2025 Nov;34(11):2318-2327. doi: 10.1007/s00044-025-03477-3. Epub 2025 Oct 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methylphenidate	Small molecule	—	Oral

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

Summary

Timeline

Publications

Drugs

Indications